IRIS
INNAO, Vanessa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.741
NA - Nord America 3.571
AS - Asia 1.797
SA - Sud America 544
Continente sconosciuto - Info sul continente non disponibili 225
AF - Africa 61
OC - Oceania 3
Totale 9.942
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.418
RU - Federazione Russa 1.786
SG - Singapore 747
BR - Brasile 466
CN - Cina 448
IT - Italia 439
IE - Irlanda 417
SE - Svezia 349
PL - Polonia 219
HK - Hong Kong 173
DE - Germania 124
FR - Francia 116
VN - Vietnam 110
IN - India 65
GB - Regno Unito 61
HU - Ungheria 61
CA - Canada 58
BD - Bangladesh 40
FI - Finlandia 37
MX - Messico 28
ID - Indonesia 27
AR - Argentina 24
BE - Belgio 22
JP - Giappone 22
IQ - Iraq 21
NL - Olanda 21
TR - Turchia 20
AT - Austria 19
PK - Pakistan 17
ZA - Sudafrica 16
ES - Italia 15
UA - Ucraina 14
PH - Filippine 13
IL - Israele 12
TT - Trinidad e Tobago 12
EG - Egitto 11
MA - Marocco 11
CO - Colombia 10
CR - Costa Rica 10
LT - Lituania 10
VE - Venezuela 10
EC - Ecuador 9
KR - Corea 9
AZ - Azerbaigian 8
CW - ???statistics.table.value.countryCode.CW??? 8
SA - Arabia Saudita 8
MY - Malesia 7
NI - Nicaragua 7
SV - El Salvador 7
UZ - Uzbekistan 7
BO - Bolivia 6
CL - Cile 6
CZ - Repubblica Ceca 6
GP - Guadalupe 6
GT - Guatemala 6
PR - Porto Rico 6
TW - Taiwan 6
JO - Giordania 5
KE - Kenya 5
PE - Perù 5
PS - Palestinian Territory 5
RO - Romania 5
SC - Seychelles 4
TN - Tunisia 4
UY - Uruguay 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
JM - Giamaica 3
KG - Kirghizistan 3
NP - Nepal 3
PY - Paraguay 3
SK - Slovacchia (Repubblica Slovacca) 3
TH - Thailandia 3
XK - ???statistics.table.value.countryCode.XK??? 3
AU - Australia 2
BH - Bahrain 2
BS - Bahamas 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EU - Europa 2
HN - Honduras 2
KZ - Kazakistan 2
LY - Libia 2
MN - Mongolia 2
OM - Oman 2
PT - Portogallo 2
RS - Serbia 2
SN - Senegal 2
SY - Repubblica araba siriana 2
AO - Angola 1
BB - Barbados 1
BG - Bulgaria 1
BM - Bermuda 1
BY - Bielorussia 1
CH - Svizzera 1
DK - Danimarca 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
Totale 9.716
Salva come PNG Salva come JPEG
Città #
Ashburn 649
Moscow 517
Singapore 434
Dublin 417
Chandler 381
Dallas 346
Nyköping 222
Warsaw 212
San Jose 207
Hong Kong 172
Messina 161
Beijing 142
The Dalles 85
Council Bluffs 81
Los Angeles 81
Princeton 76
Ann Arbor 63
Medford 63
Budapest 59
Lauterbourg 59
New York 52
Munich 50
Des Moines 47
Jacksonville 43
Santa Clara 43
Dearborn 42
São Paulo 38
Frankfurt am Main 33
Buffalo 30
Rome 29
Ho Chi Minh City 28
Dong Ket 25
Milan 25
Brussels 22
Hanoi 22
Rio de Janeiro 21
Tianjin 21
Redondo Beach 20
Brooklyn 19
Wilmington 19
Boardman 18
Cambridge 18
Chennai 18
Tokyo 18
Belo Horizonte 17
Chicago 17
Nuremberg 17
Jakarta 16
Jinan 16
Lawrenceville 16
Turku 16
Woodbridge 16
Houston 15
Montreal 15
Nanjing 14
Denver 13
Orem 13
Vienna 13
Hangzhou 12
Pune 12
Bremen 11
Guangzhou 11
North Bergen 11
Hebei 10
San Francisco 10
Johannesburg 9
San José 9
Turin 9
Brasília 8
Cairo 8
London 8
Naples 8
Ningbo 8
Palermo 8
Paris 8
Porto Alegre 8
San Mateo 8
Shanghai 8
Willemstad 8
Baku 7
Boston 7
Lahore 7
Phoenix 7
Seattle 7
Shenyang 7
Toronto 7
Zhengzhou 7
Fortaleza 6
Helsinki 6
Hillsboro 6
Istanbul 6
Madrid 6
Managua 6
Manchester 6
Mexico City 6
Poplar 6
Redwood City 6
San Salvador 6
Stockholm 6
Tashkent 6
Totale 5.668
Salva come PNG Salva come JPEG
Nome #
Altered Microrna Expression Profile in the peripheral Lymphomonocytes of Multiple Myeloma Patients with Bisphosphonate-Induced Osteonecrosis of the Jaw 314
Diagnostic utility of Sudoscan for detecting Bortezomib-induced painful neuropathy 271
A multivariate analysis of Multiple Myeloma subtype plasma cells 260
SIRT1 and SIRT2 Expression correlates with advanced disease and bone lesions in Multiple Myeloma 254
Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw 249
Altered Long Noncoding RNA Expression Profile in Multiple Myeloma Patients with Bisphosphonate-Induced Osteonecrosis of the Jaw 233
Corneal Structural Changes in Nonneoplastic and Neoplastic Monoclonal Gammopathies 214
Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells 213
A rare spinal localization of gray zone lymphoma without mediastinal involvement: A case report and review of literature 205
Evaluation of the AGE/sRAGE Axis in Patients with Multiple Myeloma 203
Anticancer Activity of Curcumin and Its Analogues: Preclinical and Clinical Studies 199
Disappearance of Acquired Hemophilia A after Complete Remission in a Multiple Myeloma Patient. 199
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant 195
Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study 194
Efficacia della chemioterapia convenzionale ad alte dosi in un caso di mieloma multiplo IgM primitivamente doppio-refrattario ai nuovi farmaci 193
Changes in serum interleukin-8 and sRAGE levels in multiple myeloma patients 188
Antiresorptive Agents and Anti-Angiogenesis Drugs in the Development of Osteonecrosis of the Jaw. 186
Vaccination of multiple myeloma: Current strategies and future prospects 185
Feasibility, Tolerability and Efficacy of Carfilzomib, Lenalidomide and Desamethasone (KRD) in Relapsed Refractory Myeloma Patients: A Real-Life Survey of the Sicilian Myeloma Network 181
Tumor Circulating Plasma Cells Detected By Flow Cytometric Single Platform Method Correlate with Clinical Response to Therapy and Unfavorable Patiets’ Characteristics 180
Telomerase and telomere biology in hematological diseases: A new therapeutic target 176
Impact of Cumulative Dose of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real Life Survey of the Sicilian Myeloma Network 174
IXAZOMIB WITH EITHER DEXAMETHASONE, CYCLOPHOSPHAMIDE-DEXAMETHASONE, THALIDOMIDE-DEXAMETHASONE OR BENDAMUSTINE-DEXAMETHASONE FOLLOWED BY IXAZOMIB MAINTENANCE IN ELDERLY NEWLY DIAGNOSED MYELOMA PATIENTS 172
The cancer stem cell hypothesis: a guide to potential molecular targets. 167
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib 165
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network 165
Vaccination strategies in lymphoproliferative disorders: Failures and successes 163
Standardisation of minimal residual disease in multiple myeloma 161
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. 158
The metabolomic signature of hematologic malignancies 155
A rare pancreatic pseudoaneurysm in patient with acute pancreatitis and multiple myeloma 153
Antitumorigenic action of nelfinavir: Effects on multiple myeloma and hematologic malignancies (Review) 153
Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies 153
Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma. 152
Role of the microbiota in hematologic malignancies. 149
The adipose organ and multiple myeloma: Impact of adipokines on tumor growth and potential sites for therapeutic intervention 138
Extramedullary plasmacytoma of the maxilla simulating a maxillary radicular cyst: Quick diagnosis and management 132
Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials 130
Nanobodies and Cancer: Current Status and New Perspectives 125
Post-chemotherapy cognitive impairment in hematological patients: current understanding of chemobrain in hematology 123
Diagnostic utility of Sudoscan for detecting bortezomib-induced painful neuropathy: a study on 18 patients with multiple myeloma 122
Preliminary Results of a Prospective Observational Study to Assess the Prevalence of Gaucher Disease in an Adult Population Affected By MGUS. 121
Quantitative polymerase Chain reaction profiling of microRNAs in peripheral lymph-monocytes from MGUS subjects 121
SIRT2 and SIRT3 expression correlates with redox imbalance and advanced clinical stage in patients with multiple myeloma 120
Lenalidomide maintenance with or without prednisone in newly diagnosed myeloma patients: A pooled analysis 112
Immune thrombocytopenia: options and new perspectives 111
Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. 109
Formaldehyde exposure and acute myeloid leukemia: A review of the literature 109
Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosphamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age 109
Mitochondria-targeted antioxidant SkQ1 for gammopathy-related corneal damage 107
The ST2/interleukin-33 axis in hematologic malignancies: The IL-33 paradox 102
Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma 101
Therapeutic potential of antagomiRs in haematological and oncological neoplasms 98
New insights into yes-associated protein signaling pathways in hematological malignancies: Diagnostic and therapeutic challenges 97
Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma 96
Relationship between mitofusin 2 and cancer. 93
Potential Role of microRNAs in inducing Drug Resistance in Patients with Multiple Myeloma 92
Selective Inhibitors of Nuclear Export in the Treatment of Hematologic Malignancies 90
Radioprotective agents and enhancers factors. Preventive and therapeutic strategies for oxidative induced radiotherapy damages in hematological malignancies 89
New orally active proteasome inhibitors in multiple myeloma. 85
Oncolytic viruses and hematological malignancies: A new class of immunotherapy drugs 85
Reviewing the significance of vitamin d substitution in monoclonal gammopathies 82
Reduced IL-33 plasma levels in multiple myeloma patients are associated with more advanced stage of disease 81
Immune checkpoint inhibitors in multiple myeloma: A review of the literature 71
New frontiers about the role of human microbiota in immunotherapy: The immune checkpoint inhibitors and CAR T-cell therapy era 70
Promising anti-mitochondrial agents for overcoming acquired drug resistance in multiple myeloma 67
null 19
Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience 3
Totale 9.942
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.932
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.932
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022424 0 0 0 0 14 11 27 19 22 96 39 196
2022/20231.257 117 130 64 120 65 121 8 70 495 11 35 21
2023/2024327 21 75 28 25 29 59 2 19 1 16 6 46
2024/20251.531 83 32 20 88 89 72 35 232 399 93 172 216
2025/20264.490 225 278 369 243 399 857 612 568 583 207 57 92
2026/2027838 102 118 228 292 98 0 0 0 0 0 0 0
Totale 9.942